Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic Syndrome (MDS) - High and Intermediate Risk”

29 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 29 results

Testing effectiveness (Phase 2)Study completedNCT01980056
What this trial is testing

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Who this might be right for
Myelodysplastic Syndrome
Weill Medical College of Cornell University 10
Testing effectiveness (Phase 2)Study completedNCT00744536
What this trial is testing

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAngiogenesis
Sunnybrook Health Sciences Centre 20
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Early research (Phase 1)WithdrawnNCT02564536
What this trial is testing

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Who this might be right for
Chronic Myelomonocytic LeukemiaJuvenile Myelomonocytic LeukemiaAtypical Chronic Myeloid Leukemia+3 more
Washington University School of Medicine
Large-scale testing (Phase 3)UnknownNCT05175508
What this trial is testing

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Who this might be right for
AMLMDSOld Age; Debility+1 more
The First Affiliated Hospital of Soochow University 180
Large-scale testing (Phase 3)Ended earlyNCT02158936
What this trial is testing

Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Thrombocytopaenia
Novartis Pharmaceuticals 356
Testing effectiveness (Phase 2)Ended earlyNCT00185679
What this trial is testing

Haploid Allogeneic Transplant Using the CliniMACS System

Who this might be right for
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk FactorsChronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic PhaseMyelodysplastic Syndrome (MDS) - High and Intermediate Risk+2 more
Ginna Laport 13
Early research (Phase 1)Study completedNCT04402541
What this trial is testing

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndromes
Cleave Therapeutics, Inc. 55
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Post-approval studies (Phase 4)Ended earlyNCT01011283
What this trial is testing

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Who this might be right for
Myelodysplastic Syndromes
Eisai Inc. 26
Testing effectiveness (Phase 2)Ended earlyNCT05835011
What this trial is testing

Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Astex Pharmaceuticals, Inc. 2
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Early research (Phase 1)WithdrawnNCT03057990
What this trial is testing

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Montefiore Medical Center
Early research (Phase 1)Study completedNCT05048498
What this trial is testing

Pharmacokinetics, Tolerability and Safety of NEX-18a

Who this might be right for
Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
Nanexa AB 2
Testing effectiveness (Phase 2)Looking for participantsNCT07238686
What this trial is testing

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

Who this might be right for
Myelodysplastic Syndromes
Beijing 302 Hospital 40
Testing effectiveness (Phase 2)Study completedNCT00439673
What this trial is testing

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Gruppo Italiano Malattie EMatologiche dell'Adulto 62
Testing effectiveness (Phase 2)UnknownNCT00838240
What this trial is testing

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

Who this might be right for
LeukemiaMyelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 114
Testing effectiveness (Phase 2)Study completedNCT02018926
What this trial is testing

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Who this might be right for
Myelodysplastic Syndrome
Mirati Therapeutics Inc. 18
Early research (Phase 1)Study completedNCT03516591
What this trial is testing

AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome (MDS)
Amphivena Therapeutics, Inc. 14
Load More Results